BR112022018877A2 - Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd - Google Patents
Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phdInfo
- Publication number
- BR112022018877A2 BR112022018877A2 BR112022018877A BR112022018877A BR112022018877A2 BR 112022018877 A2 BR112022018877 A2 BR 112022018877A2 BR 112022018877 A BR112022018877 A BR 112022018877A BR 112022018877 A BR112022018877 A BR 112022018877A BR 112022018877 A2 BR112022018877 A2 BR 112022018877A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- pulmonary
- compounds
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992585P | 2020-03-20 | 2020-03-20 | |
| PCT/US2021/023219 WO2021188936A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018877A2 true BR112022018877A2 (pt) | 2022-11-29 |
Family
ID=75639962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018877A BR112022018877A2 (pt) | 2020-03-20 | 2021-03-19 | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230227426A1 (https=) |
| EP (1) | EP4121425A1 (https=) |
| JP (2) | JP7768890B2 (https=) |
| KR (1) | KR20220156889A (https=) |
| CN (2) | CN119823097A (https=) |
| AR (1) | AR121618A1 (https=) |
| AU (1) | AU2021239378A1 (https=) |
| BR (1) | BR112022018877A2 (https=) |
| CA (1) | CA3176140A1 (https=) |
| CO (1) | CO2022014490A2 (https=) |
| IL (1) | IL296631A (https=) |
| MX (1) | MX2022011123A (https=) |
| TW (1) | TW202140443A (https=) |
| WO (1) | WO2021188936A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| CN115991698B (zh) * | 2022-11-03 | 2024-03-29 | 广东中科药物研究有限公司 | 一种杂环化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA031647B1 (ru) | 2013-03-29 | 2019-02-28 | Такеда Фармасьютикал Компани Лимитед | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |
-
2021
- 2021-03-19 AR ARP210100691A patent/AR121618A1/es unknown
- 2021-03-19 MX MX2022011123A patent/MX2022011123A/es unknown
- 2021-03-19 AU AU2021239378A patent/AU2021239378A1/en active Pending
- 2021-03-19 WO PCT/US2021/023219 patent/WO2021188936A1/en not_active Ceased
- 2021-03-19 TW TW110109982A patent/TW202140443A/zh unknown
- 2021-03-19 JP JP2022556170A patent/JP7768890B2/ja active Active
- 2021-03-19 CN CN202510216379.8A patent/CN119823097A/zh active Pending
- 2021-03-19 CA CA3176140A patent/CA3176140A1/en active Pending
- 2021-03-19 EP EP21720873.5A patent/EP4121425A1/en active Pending
- 2021-03-19 US US17/906,650 patent/US20230227426A1/en active Pending
- 2021-03-19 KR KR1020227036362A patent/KR20220156889A/ko active Pending
- 2021-03-19 IL IL296631A patent/IL296631A/en unknown
- 2021-03-19 CN CN202180034124.XA patent/CN115551845B/zh active Active
- 2021-03-19 BR BR112022018877A patent/BR112022018877A2/pt unknown
-
2022
- 2022-10-12 CO CONC2022/0014490A patent/CO2022014490A2/es unknown
-
2025
- 2025-10-30 JP JP2025183157A patent/JP2026021443A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011123A (es) | 2023-01-04 |
| AU2021239378A1 (en) | 2022-11-17 |
| TW202140443A (zh) | 2021-11-01 |
| CN115551845A (zh) | 2022-12-30 |
| CA3176140A1 (en) | 2021-09-23 |
| US20230227426A1 (en) | 2023-07-20 |
| CO2022014490A2 (es) | 2022-10-21 |
| EP4121425A1 (en) | 2023-01-25 |
| JP2023518953A (ja) | 2023-05-09 |
| AR121618A1 (es) | 2022-06-22 |
| WO2021188936A1 (en) | 2021-09-23 |
| CN119823097A (zh) | 2025-04-15 |
| KR20220156889A (ko) | 2022-11-28 |
| CN115551845B (zh) | 2025-02-28 |
| JP7768890B2 (ja) | 2025-11-12 |
| JP2026021443A (ja) | 2026-02-10 |
| IL296631A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018877A2 (pt) | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd | |
| BR112022018878A2 (pt) | Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd | |
| JP6526306B2 (ja) | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 | |
| BR112023003492A2 (pt) | Composto de fórmula (i), composição farmacêutica e uso do composto | |
| JP2018518537A5 (https=) | ||
| JP2022008860A5 (https=) | ||
| CN107708697B (zh) | 纤维化病治疗剂 | |
| US20180000816A1 (en) | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions | |
| US20220281845A1 (en) | Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds | |
| WO2005120497A2 (en) | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof | |
| BG63944B1 (bg) | Производни на хидроксиламина, които се използват за повишаване продуцирането на молекулен чаперон исъстав | |
| JP2016522831A (ja) | 炎症を予防および治療するためのクリオピリン阻害剤 | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| US20180273485A1 (en) | Cannabinoid receptor mediating compounds | |
| JP2015536997A (ja) | カンナビノイド受容体媒介性化合物 | |
| JP2017507915A5 (https=) | ||
| BR112018069930B1 (pt) | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica | |
| JP2020524178A (ja) | ファルネソイドｘ受容体および可溶性エポキシドヒドロラーゼの二重調節剤 | |
| US20170042890A1 (en) | Methods of reducing decline in vital capacity | |
| KR20220127826A (ko) | 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도 | |
| US12605378B2 (en) | Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of SARS-CoV-2 | |
| JP2023505598A (ja) | 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP2009504762A5 (https=) | ||
| CO2023000129A2 (es) | Agonistas de pirazolona del receptor 2 del péptido formilo | |
| JP2019535826A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025027331-7 PROTOCOLO 870250113367 EM 09/12/2025 20:06. |